Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

This study has been completed.
Information provided by:
Amgen Identifier:
First received: July 25, 2005
Last updated: February 25, 2010
Last verified: February 2010